OPRX vs. RMNI, LLNW, RGP, OLO, VVI, CNDT, XMTR, IMXI, IIIV, and LQDT
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), Limelight Networks (LLNW), Resources Connection (RGP), OLO (OLO), Viad (VVI), Conduent (CNDT), Xometry (XMTR), International Money Express (IMXI), i3 Verticals (IIIV), and Liquidity Services (LQDT).
OptimizeRx (NASDAQ:OPRX) and Rimini Street (NASDAQ:RMNI) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
OptimizeRx currently has a consensus target price of $16.00, suggesting a potential upside of 40.35%. Rimini Street has a consensus target price of $4.50, suggesting a potential upside of 58.45%. Given Rimini Street's higher possible upside, analysts clearly believe Rimini Street is more favorable than OptimizeRx.
In the previous week, OptimizeRx had 1 more articles in the media than Rimini Street. MarketBeat recorded 2 mentions for OptimizeRx and 1 mentions for Rimini Street. OptimizeRx's average media sentiment score of 0.00 equaled Rimini Street'saverage media sentiment score.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Rimini Street received 9 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.16% of users gave OptimizeRx an outperform vote.
OptimizeRx has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Rimini Street has a net margin of 5.02% compared to OptimizeRx's net margin of -23.10%. OptimizeRx's return on equity of -6.96% beat Rimini Street's return on equity.
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 73.8% of Rimini Street shares are held by institutional investors. 4.4% of OptimizeRx shares are held by company insiders. Comparatively, 41.3% of Rimini Street shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Rimini Street beats OptimizeRx on 10 of the 17 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
